Media stories about XOMA (NASDAQ:XOMA) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. XOMA earned a daily sentiment score of 0.16 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 47.5280837175341 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the media stories that may have impacted Accern Sentiment’s analysis:
- Biopharmaceutical Veteran Joins CURE Pharmaceutical to Lead Manufacturing (forextv.com)
- XOMA (XOMA) Rating Increased to Hold at ValuEngine (americanbankingnews.com)
- XOMA (XOMA) Downgraded by Zacks Investment Research (americanbankingnews.com)
- XOMA (XOMA) Given a $49.00 Price Target at HC Wainwright (americanbankingnews.com)
- XOMA Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update (finance.yahoo.com)
Several equities research analysts recently weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $49.00 price target on shares of XOMA in a research report on Thursday, January 18th. ValuEngine upgraded shares of XOMA from a “sell” rating to a “hold” rating in a research report on Friday, March 9th. Wedbush restated a “buy” rating and issued a $33.00 price target on shares of XOMA in a research report on Tuesday, December 19th. Zacks Investment Research cut shares of XOMA from a “hold” rating to a “sell” rating in a research report on Friday, March 9th. Finally, TheStreet upgraded shares of XOMA from an “e+” rating to a “c-” rating in a research report on Wednesday, November 29th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $38.33.
XOMA (NASDAQ:XOMA) last posted its quarterly earnings data on Wednesday, March 7th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.35) by $0.19. XOMA had a net margin of 27.49% and a negative return on equity of 130.44%. The business had revenue of $5.36 million for the quarter, compared to analysts’ expectations of $4.12 million. equities research analysts forecast that XOMA will post -0.62 earnings per share for the current fiscal year.
XOMA Company Profile
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.